Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company is known for its innovative approach to treating conditions like depression and migraines. In the competitive healthcare sector, Axsome stands out with its commitment to addressing unmet medical needs.On December 4, 2025, Herriot Tabuteau, the CEO and a significant shareholder of Axsome, sold 10,558 shares of the company's common stock at $148.18 each. This ...

Core Viewpoint - NLS Pharmaceutics Ltd. has undergone a significant transformation through a reverse stock split and a merger with Kadimastem Ltd., resulting in the formation of NewcelX Ltd. to enhance its focus on developing therapies for central nervous system disorders [1][2][5]. Group 1: Merger and Corporate Changes - The merger between NLS Pharmaceutics and Kadimastem was finalized on October 30, 2025, leading to the creation of NewcelX Ltd., which will trade on the Nasdaq Capital Market under the ticker symbol "NCEL" starting October 31, 2025 [2]. - The reverse stock split executed at a ratio of 10 for 1 is part of a broader strategy to strengthen the company's market position [1][3]. - The traded warrants of the company will be delisted following the merger [3]. Group 2: Financial Performance - Currently, NLSP's stock price is $0.762, reflecting an increase of 2.97% or $0.022, with a trading volume of 30.3 million shares on the NASDAQ exchange [4][5]. - The company's market capitalization stands at approximately $2.4 million, with the stock having traded between a low of $0.76 and a high of $0.83 on the day of reporting [4]. - Over the past year, the stock has reached a high of $47.4 and a low of $0.76 [4].